BioWorld – Halia closes a $30M series C to develop inflammasome inhibitors
February 1, 2024

Lee Landenberger
January 31, 2024

Dr David Bearss who leads Halia Therapeutics in developing inflammasome inhibitors

Halia Therapeutics Inc. has, its CEO confidently asserts, taken an atypical road to building its infrastructure and financing. The Lehi, Utah-based company just completed a $30 million series C financing to further develop its lead asset, a selective and orally bioavailable first-in-class NLRP3/NEK7 inflammasome inhibitor.

See the full article at the link below.

To learn more about the inflammasome inhibitors we are developing visit our pipeline page.